ArticleJournal of molecular histology2026
β-Ionone inhibits A. sydowii mediated LUAD progression by inhibiting myeloid-derived suppressor cell (MDSC) expansion and activation.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fungal dysbiosis can be associated with the carcinogenesis of malignant tumors, and recent studies have indicated that Aspergillus sydowii (A. sydowii) plays a role in the pathogenesis of lung adenocarcinoma (LUAD). However, current research lacks effective treatment options for LUAD infected with A. sydowii. Therefore, the aim of this study was to investigate the therapeutic effects and mechanisms of β-ionone. Lewis lung cancer (LLC) cell xenograft tumor mouse model was constructed, and A. sydowii or various concentrations of β-ionone were treated. Subsequently, tumor volume and mass were monitored. Fluorescence in situ hybridization (FISH) staining with the D223 28S rRNA probe was employed to assess the abundance of fungi within the tumors. Additionally, immunohistochemical staining, flow cytometry, and ELISA were utilized to analyze the function of myeloid-derived suppressor cells (MDSCs) within the tumor. This study revealed that compared to the control group, A. sydowii-infected mice exhibited significantly increased tumor volume and mass (P < 0.001), enhanced Ki-67 staining intensity in tumor tissues (P < 0.01), and elevated fungal abundance within the tumor microenvironment (P < 0.001). Furthermore, A. sydowii promoted the expansion and functional activation of CD11b+ Gr1+ MDSCs. In contrast, β-ionone treatment suppressed LUAD tumor growth while concurrently inhibiting MDSC functional activation. Mechanistic investigations demonstrated that β-ionone exerts its anti-tumor and anti-fungal effects by suppressing the activation of the CARD9/p38 MAPK signaling pathway. β-ionone exhibits antitumor activity in A. sydowii-induced LUAD, which supports the potential clinical application of β-ionone in lung cancer therapy.
Indexed as
Identifiers
41524781What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.